Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
70
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

408
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
408
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
118
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

95
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
95
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

76
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
76
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

486
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
486

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapy.

Biochemistry and biophysics reports·2026
Same author

Pharmacological inhibition of LIF signaling reverses PD-L1-mediated immune suppression in gastric cancer.

Translational oncology·2026
Same author

Eosinophilic Esophagitis and Lymphocytic Esophagitis: Convergent Symptoms, Divergent Biology.

Recent advances in inflammation & allergy drug discovery·2026
Same author

NF-κB in Drug Discovery: Still an Elusive Target.

Recent advances in inflammation & allergy drug discovery·2026
Same author

A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitis.

Gut microbes·2026
Same author

Secondary bile acids as immune and metabolic mediators.

Trends in immunology·2026

Related Experiment Video

Updated: Jun 12, 2025

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts
09:55

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts

Published on: May 16, 2020

3.8K

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis.

Stefano Fiorucci1, Ginevra Urbani1, Cristina Di Giorgio1

  • 1Dipartimento di Medicina e Chirurgia, Università di Perugia, 06123 Perugia, Italy.

Cells
|September 27, 2024
PubMed
Summary

Primary Biliary Cholangitis (PBC) is an autoimmune liver disease. New therapies targeting bile acids and PPAR agonists show promise for improving treatment outcomes and personalizing patient care.

Keywords:
T cellscholangiocytescholestasisfarnesoid-x-receptor (FXR)macrophagesperoxisome-proliferator-associated receptors (PPAR)

More Related Videos

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.5K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

2.4K

Related Experiment Videos

Last Updated: Jun 12, 2025

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts
09:55

Generation and Quantitative Characterization of Functional and Polarized Biliary Epithelial Cysts

Published on: May 16, 2020

3.8K
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.5K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

2.4K

Area of Science:

  • Hepatology
  • Immunology
  • Gastroenterology

Background:

  • Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease causing progressive cholestasis.
  • Genetic predisposition and environmental factors contribute to PBC pathogenesis, with gut microbiota dysbiosis as a potential factor.
  • Cholangiocyte senescence and bile acid dysregulation are key mechanisms in PBC progression.

Purpose of the Study:

  • To review published and ongoing clinical trials for Primary Biliary Cholangitis (PBC).
  • To examine novel therapeutic approaches beyond current bile acid-based therapies.
  • To discuss the potential of new treatments like PPAR agonists in PBC management.

Main Methods:

  • Review of clinical trial data and scientific literature on PBC therapies.
  • Analysis of emerging treatment strategies including elafibranor and seladelpar.
  • Exploration of the role of bile acids and cholangiocyte senescence in disease progression.

Main Results:

  • Ursodeoxycholic acid and obeticholic acid are established PBC therapies.
  • Recently approved PPAR agonists (elafibranor, seladelpar) represent novel second-line treatment options.
  • Ongoing trials are evaluating new agents to improve PBC therapy.

Conclusions:

  • Novel therapies, including PPAR agonists, are expected to enhance PBC treatment efficacy.
  • The development of personalized approaches in PBC management is advancing.
  • Further research into pathogenic mechanisms and therapeutic targets is crucial for improved patient outcomes.